Study

EORTC-75111-10114

Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH/PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 18-Jun-2013
Date Step1 close: 12-May-2016

Data management at EORTC

Yes

Design

Phase 2
Randomized open label

Targeted Sample size

EORTC Groups: 80 - All Groups: 80

Protocol summary

http://clinicaltrials.gov/study/NCT01597414

NCT number

NCT01597414

EudraCT

2011-006342-32